{"id":"clobetasol","_fda":{"id":"734aafd4-05a6-4c72-a08a-fb0ca7ba8809","set_id":"032f1f4e-1f1c-409a-8fac-6449ee543caa","openfda":{"unii":["779619577M"],"route":["TOPICAL"],"rxcui":["861448"],"spl_id":["734aafd4-05a6-4c72-a08a-fb0ca7ba8809"],"brand_name":["Clobetasol Propionate"],"spl_set_id":["032f1f4e-1f1c-409a-8fac-6449ee543caa"],"package_ndc":["63629-2456-1"],"product_ndc":["63629-2456"],"generic_name":["CLOBETASOL PROPIONATE OINTMENT USP, 0.05%"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CLOBETASOL PROPIONATE"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA211295"],"original_packager_product_ndc":["21922-017"]},"version":"107","pregnancy":["Pregnancy: Teratogenic Effects: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less potent. Teratogenicity studies in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and teratogenicity at all dose levels tested down to 0.03 mg/kg. These doses are approximately 1.4 and 0.04 times, respectively, the human topical dose of clobetasol propionate ointment. Abnormalities seen included cleft palate and skeletal abnormalities. In rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.02 and 0.05 times, respectively, the human topical dose of clobetasol propionate ointment. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. There are no adequate and well-controlled studies of the teratogenic potential of clobetasol propionate in pregnant women. Clobetasol propionate ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE Topically applied clobetasol propionate ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS )."],"description":["DESCRIPTION Clobetasol propionate ointment USP contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Chemically, clobetasol propionate is (11β, 16β)-21-chloro-9-fluoro-11-hydroxy-16-methyt-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione, and it has the following structural formula: Clobetasol propionate has the empirical formula C 25 H 32 ClFO 5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water. Clobetasol propionate ointment USP, 0.05% contains clobetasol propionate 0.5 mg/g in a base of propylene glycol, sorbitan sesquioleate, and white petrolatum."],"precautions":["PRECAUTIONS General: Clobetasol propionate ointment USP, 0.05% should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on therapy. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time, and only small areas should be treated at any one time due to the increased risk of HPA suppression. Clobetasol propionate ointment produced HPA axis suppression when used at doses as low as 2 g/day for 1 week in patients with eczema. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur that require supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use ). If irritation develops, clobetasol propionate ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of clobetasol propionate ointment should be discontinued until the infection has been adequately controlled. Information for Patients: Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. The treated skin area should not be bandaged, otherwise covered, or wrapped so as to be occlusive unless directed by the physician. 4. Patients should report any signs of local adverse reactions to the physician. Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test, A.M. plasma cortisol test, Urinary free cortisol test. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate. Studies in the rat following subcutaneous administration at dosage levels up to 50 mcg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Clobetasol propionate was nonmutagenic in 3 different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test. Pregnancy: Teratogenic Effects: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less potent. Teratogenicity studies in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and teratogenicity at all dose levels tested down to 0.03 mg/kg. These doses are approximately 1.4 and 0.04 times, respectively, the human topical dose of clobetasol propionate ointment. Abnormalities seen included cleft palate and skeletal abnormalities. In rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.02 and 0.05 times, respectively, the human topical dose of clobetasol propionate ointment. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. There are no adequate and well-controlled studies of the teratogenic potential of clobetasol propionate in pregnant women. Clobetasol propionate ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when either clobetasol propionate ointment is administered to a nursing woman. Pediatric Use: Safety and effectiveness of clobetasol propionate ointment in pediatric patients have not been established. Use in pediatric patients under 12 years of age is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Geriatric Use: A limited number of patients at or above 65 years of age have been treated with clobetasol propionate ointment (n = 101) in US and non-US clinical trials. While the number of patients is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger patients. Based on available data, no adjustment of dosage of clobetasol propionate ointment in geriatric patients is warranted."],"how_supplied":["HOW SUPPLIED Clobetasol Propionate Ointment USP, 0.05% is supplied in: 45 g tube (NDC 63629-2456-1) Store at controlled room temperature 15°-30°C (59°-86°F). DO NOT REFRIGERATE. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["Geriatric Use: A limited number of patients at or above 65 years of age have been treated with clobetasol propionate ointment (n = 101) in US and non-US clinical trials. While the number of patients is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger patients. Based on available data, no adjustment of dosage of clobetasol propionate ointment in geriatric patients is warranted."],"pediatric_use":["Pediatric Use: Safety and effectiveness of clobetasol propionate ointment in pediatric patients have not been established. Use in pediatric patients under 12 years of age is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema."],"effective_time":"20250124","nursing_mothers":["Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when either clobetasol propionate ointment is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test, A.M. plasma cortisol test, Urinary free cortisol test."],"adverse_reactions":["ADVERSE REACTIONS In controlled clinical trials, the most frequent adverse events reported for clobetasol propionate ointment were burning sensation, irritation, and itching in 0.5% of treated patients. Less frequent adverse reactions were stinging, cracking, erythema, folliculitis, numbness of fingers, skin atrophy, and telangiectasia Cushing's syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Clobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations."],"general_precautions":["General: Clobetasol propionate ointment USP, 0.05% should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on therapy. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time, and only small areas should be treated at any one time due to the increased risk of HPA suppression. Clobetasol propionate ointment produced HPA axis suppression when used at doses as low as 2 g/day for 1 week in patients with eczema. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur that require supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use ). If irritation develops, clobetasol propionate ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of clobetasol propionate ointment should be discontinued until the infection has been adequately controlled."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released frommembrane phospholipids by phospholipase A 2 . Pharmacokinetics : The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressing with hydrocortisone for up to 24 hours has not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with clobetasol propionate ointment indicate that it is in the super-high range of potency as compared with other topical corticosteroids."],"indications_and_usage":["INDICATIONS AND USAGE Clobetasol propionate ointment USP, 0.05% is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary."],"information_for_patients":["Information for Patients: Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. The treated skin area should not be bandaged, otherwise covered, or wrapped so as to be occlusive unless directed by the physician. 4. Patients should report any signs of local adverse reactions to the physician."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Apply a thin layer of clobetasol propionate ointment to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE .) Clobetasol propionate ointment are super- high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks , and amounts greater than 50 g per week should not be used . As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol propionate ointment should not be used with occlusive dressings . Geriatric Use : In studies where geriatric patients (65 years of age or older, see PRECAUTIONS ) have been treated with clobetasol propionate ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended."],"spl_product_data_elements":["Clobetasol Propionate Clobetasol Propionate Ointment USP, 0.05% CLOBETASOL PROPIONATE CLOBETASOL SORBITAN SESQUIOLEATE PROPYLENE GLYCOL PETROLATUM Structure 2"],"package_label_principal_display_panel":["Clobetasol Propionate 0.05% Ointment Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate. Studies in the rat following subcutaneous administration at dosage levels up to 50 mcg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Clobetasol propionate was nonmutagenic in 3 different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Burning and/or stinging sensation","drugRate":"9.86%","severity":"common","organSystem":""},{"effect":"Scalp pustules","drugRate":"1.02%","severity":"common","organSystem":""},{"effect":"Tingling","drugRate":"0.68%","severity":"common","organSystem":""},{"effect":"Folliculitis","drugRate":"0.68%","severity":"common","organSystem":""},{"effect":"Itching","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Tightness of the scalp","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Dermatitis","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Tenderness","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Hair loss","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Eye irritation","drugRate":"0.34%","severity":"common","organSystem":""},{"effect":"Burning","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Irritation","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Dryness","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Hypertrichosis","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Acneiform eruptions","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Hypopigmentation","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Perioral dermatitis","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Allergic contact dermatitis","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Maceration of the skin","drugRate":"","severity":"infrequent","organSystem":""}],"seriousAdverseEvents":[{"effect":"HPA axis suppression","drugRate":"","severity":"serious"},{"effect":"Cushing's syndrome manifestations","drugRate":"","severity":"serious"},{"effect":"Hyperglycemia","drugRate":"","severity":"serious"},{"effect":"Glucosuria","drugRate":"","severity":"serious"},{"effect":"Secondary infection","drugRate":"","severity":"serious"},{"effect":"Skin atrophy","drugRate":"","severity":"serious"},{"effect":"Striae","drugRate":"","severity":"serious"},{"effect":"Miliaria","drugRate":"","severity":"serious"},{"effect":"Exacerbation of psoriasis","drugRate":"","severity":"serious"},{"effect":"Pustular psoriasis","drugRate":"","severity":"serious"}]},"_chembl":{"chemblId":"CHEMBL1201362","moleculeType":"Small molecule","molecularWeight":"410.91"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CLOBETASOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:40:09.473556+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:40:16.917937+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOBETASOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:40:17.697355+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:07.394887+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:07.394919+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201362/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:40:18.172011+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA211295","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:07.394926+00:00"}},"_dailymed":{"setId":"4a761afb-a48a-4a5a-8700-ad93601a260f","title":"CLOBETASOL PROPIONATE GEL CLOBETASOL PROPIONATE CREAM CLOBETASOL PROPIONATE OINTMENT [SUN PHARMACEUTICAL INDUSTRIES, INC.]"},"_scrapedAt":"2026-03-28T00:45:02.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:40:22.787415+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04563923","phase":"PHASE2","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-10-10","conditions":"Bullous Pemphigoid","enrollment":15},{"nctId":"NCT03926299","phase":"NA","title":"Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Prof. Dr. Volker Viereck","startDate":"2019-07-15","conditions":"Chronic Skin Disease, Vulvar Lichen Sclerosus","enrollment":66},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT07398807","phase":"EARLY_PHASE1","title":"Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo","status":"RECRUITING","sponsor":"Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan","startDate":"2025-08-08","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT02360202","phase":"PHASE4","title":"Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2015-02-17","conditions":"Bullous Pemphigoid","enrollment":30},{"nctId":"NCT05493280","phase":"NA","title":"Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-14","conditions":"Hyperpigmentation","enrollment":15},{"nctId":"NCT07278999","phase":"NA","title":"Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus.","status":"RECRUITING","sponsor":"Medical University of Silesia","startDate":"2025-12-01","conditions":"Oral Lichen Planus, Erosive Lichen Planus, Mucosal Lesions","enrollment":60},{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":"Post Cataract Surgery","enrollment":40},{"nctId":"NCT05010421","phase":"PHASE3","title":"Laser vs Clobetasol for Lichen Sclerosus","status":"COMPLETED","sponsor":"Ruhr University of Bochum","startDate":"2021-11-02","conditions":"Lichen Sclerosus","enrollment":246},{"nctId":"NCT07240519","phase":"NA","title":"To Compare Inflammatory Biomarkers Before and After Treatment With Clobetasol or Fractional CO2 Laser, in Women With Histologically Confirmed Vulvar Lichen Sclerosus, Without Prior Corticosteroid Treatment.","status":"RECRUITING","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2022-06-22","conditions":"Vulvar Lichen Sclerosus","enrollment":40},{"nctId":"NCT06742333","phase":"PHASE2","title":"Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-07-22","conditions":"Psoriasis","enrollment":40},{"nctId":"NCT07240389","phase":"NA","title":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Milosz Pietrus","startDate":"2025-12-01","conditions":"Vulvar Lichen Sclerosus","enrollment":45},{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":250},{"nctId":"NCT06135402","phase":"NA","title":"Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus","status":"RECRUITING","sponsor":"Kantonsspital Winterthur KSW","startDate":"2023-11-10","conditions":"Lichen Sclerosus","enrollment":120},{"nctId":"NCT06856590","phase":"NA","title":"ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction","status":"COMPLETED","sponsor":"Gazi University","startDate":"2025-02-20","conditions":"Hand-Foot Skin Reaction (HFSR)","enrollment":150},{"nctId":"NCT07100613","phase":"PHASE2","title":"Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus","status":"RECRUITING","sponsor":"University of Palermo","startDate":"2024-09-04","conditions":"Oral Lichen Planus, Oral Lichen Planus Related Stress, Oral Mucosal Disease","enrollment":45},{"nctId":"NCT05706870","phase":"PHASE2","title":"Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis","status":"COMPLETED","sponsor":"GEN İlaç ve Sağlık Ürünleri A.Ş.","startDate":"2022-12-07","conditions":"Psoriasis","enrollment":190},{"nctId":"NCT05243563","phase":"PHASE2, PHASE3","title":"Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?","status":"TERMINATED","sponsor":"University of South Alabama","startDate":"2022-04-13","conditions":"Vulvar Lichen Sclerosus","enrollment":11},{"nctId":"NCT02368886","phase":"PHASE2","title":"Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2015-03-27","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7","enrollment":123},{"nctId":"NCT01557517","phase":"PHASE2","title":"Clobetasol for Oral Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-28","conditions":"Oral Chronic Graft vs Host Disease","enrollment":40},{"nctId":"NCT04951206","phase":"PHASE4","title":"Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2022-03-01","conditions":"Vulvar Lichen Sclerosus","enrollment":212},{"nctId":"NCT05364515","phase":"PHASE3","title":"Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva","status":"WITHDRAWN","sponsor":"Fundación Eduardo Anitua","startDate":"2021-12-23","conditions":"Lichen Sclerosus of Vulva","enrollment":""},{"nctId":"NCT02392130","phase":"PHASE1","title":"A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-03","conditions":"Skin Tissue Diseases, Connective Tissue Diseases","enrollment":40},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT02355639","phase":"PHASE1","title":"A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Skin and Connective Tissue Diseases","enrollment":16},{"nctId":"NCT01043224","phase":"PHASE1","title":"A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-01","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT06752343","phase":"PHASE2","title":"A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised Controlled Study","status":"COMPLETED","sponsor":"Wroclaw Medical University","startDate":"2023-06-01","conditions":"Oral Lichen Planus","enrollment":29},{"nctId":"NCT04364555","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Malmö University","startDate":"2020-05-18","conditions":"Oral Lichen Planus","enrollment":90},{"nctId":"NCT05724446","phase":"PHASE3","title":"Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population","status":"RECRUITING","sponsor":"Salvat","startDate":"2022-12-12","conditions":"Cataracts Infantile","enrollment":60},{"nctId":"NCT06555497","phase":"EARLY_PHASE1","title":"Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis","status":"COMPLETED","sponsor":"Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium","startDate":"2022-01-01","conditions":"Pilot Study, Psoriasis","enrollment":2},{"nctId":"NCT06363539","phase":"PHASE2","title":"Silver Nitrate Versus Topical Steroid For Umbilical Granuloma","status":"COMPLETED","sponsor":"Children Hospital and Institute of Child Health, Lahore","startDate":"2022-09-20","conditions":"Umbilical Granuloma","enrollment":354},{"nctId":"NCT03179605","phase":"PHASE2","title":"Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06","status":"TERMINATED","sponsor":"Primus Pharmaceuticals","startDate":"2017-05-02","conditions":"Psoriasis","enrollment":22},{"nctId":"NCT06148090","phase":"NA","title":"Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2024-01-04","conditions":"Pemphigoid, Bullous, Adrenal Insufficiency","enrollment":50},{"nctId":"NCT04220554","phase":"NA","title":"Improvement of Psoriasis Patients' Adherence to Topical Drugs","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2020-06-19","conditions":"Psoriasis Vulgaris","enrollment":103},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT06119672","phase":"PHASE3","title":"Efficacy of Probiotic Capsules With Topical Clobetasol Propionate in OLP Treatment","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-05-01","conditions":"Oral Lichen Planus","enrollment":36},{"nctId":"NCT04649697","phase":"PHASE3","title":"Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-12-01","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT05818618","phase":"NA","title":"Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Catania","startDate":"2020-03-12","conditions":"Oral Lichen Planus","enrollment":64},{"nctId":"NCT00400725","phase":"PHASE3","title":"Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-09-29","conditions":"Scalp Psoriasis","enrollment":288},{"nctId":"NCT05428202","phase":"PHASE1","title":"Phase I Study of GN-037 Cream for Psoriasis","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2022-03-28","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT05885269","phase":"PHASE1","title":"Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2022-11-01","conditions":"Alopecia Areata","enrollment":70},{"nctId":"NCT03926377","phase":"PHASE4","title":"Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-04-01","conditions":"Osteoporosis, Bullous Pemphigoid","enrollment":50},{"nctId":"NCT04246801","phase":"PHASE3","title":"Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)","status":"COMPLETED","sponsor":"Salvat","startDate":"2020-06-10","conditions":"Cataract","enrollment":250},{"nctId":"NCT04249076","phase":"PHASE3","title":"Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)","status":"COMPLETED","sponsor":"Salvat","startDate":"2020-06-04","conditions":"Cataract","enrollment":215},{"nctId":"NCT01893567","phase":"PHASE4","title":"Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT00881868","phase":"PHASE4","title":"Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-04","conditions":"Scalp Psoriasis","enrollment":81},{"nctId":"NCT00733954","phase":"PHASE4","title":"Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-08","conditions":"Plaque Psoriasis","enrollment":250},{"nctId":"NCT00658788","phase":"PHASE3","title":"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-03","conditions":"Psoriasis","enrollment":305},{"nctId":"NCT00988637","phase":"PHASE4","title":"Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-10","conditions":"Plaque Psoriasis","enrollment":138},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT00436540","phase":"PHASE4","title":"A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-03","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT00437216","phase":"","title":"Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Psoriasis","enrollment":2488},{"nctId":"NCT04719962","phase":"NA","title":"Direct Diagnosis of Disseminated Lyme Borreliosis.","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-07-07","conditions":"Lyme Disease","enrollment":10},{"nctId":"NCT01126255","phase":"PHASE2","title":"Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2011-03","conditions":"Vulvar Lichen Sclerosus","enrollment":37},{"nctId":"NCT05228483","phase":"NA","title":"Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-11-23","conditions":"Vulva Lichen Sclerosus","enrollment":134},{"nctId":"NCT02313870","phase":"PHASE3","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-01-22","conditions":"Bullous Pemphigoid","enrollment":322},{"nctId":"NCT00803439","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2005-04","conditions":"Healthy","enrollment":80},{"nctId":"NCT02573883","phase":"PHASE3","title":"Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2015-10","conditions":"Vulvar Lichen Sclerosus","enrollment":52},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT03847389","phase":"PHASE1, PHASE2","title":"Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Hill Dermaceuticals, Inc.","startDate":"2019-09-09","conditions":"Atopic Dermatitis","enrollment":8},{"nctId":"NCT01282515","phase":"PHASE2, PHASE3","title":"Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2011-08","conditions":"Genital Lichen Planus","enrollment":40},{"nctId":"NCT00438399","phase":"PHASE3","title":"Subject Preference for Scalp Psoriasis Treatment","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Scalp Psoriasis","enrollment":219},{"nctId":"NCT00862654","phase":"PHASE3","title":"Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-03","conditions":"Scalp Seborrheic Dermatitis","enrollment":326},{"nctId":"NCT04719559","phase":"NA","title":"Fractional Laser and Steroid Ointment to Improve the Old Scar After Thyroidectomy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-03-20","conditions":"Thyroid; Wound, Steroid Acne","enrollment":10},{"nctId":"NCT04685031","phase":"PHASE1, PHASE2","title":"Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis","status":"UNKNOWN","sponsor":"Komar University of Science and Technology","startDate":"2021-02-01","conditions":"Phlebitis","enrollment":110},{"nctId":"NCT04673916","phase":"NA","title":"Treatment Protocols for Patients With Symptomatic Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Messina","startDate":"2019-06-01","conditions":"Lichen Planus, Oral, Preneoplastic Condition","enrollment":61},{"nctId":"NCT01591785","phase":"NA","title":"Treatment of Staphylococcus Aureus Colonization in Hand Eczema","status":"COMPLETED","sponsor":"Gary Goldenberg","startDate":"2012-01","conditions":"Hand Eczema, Foot Eczema","enrollment":60},{"nctId":"NCT03878771","phase":"PHASE1","title":"PRF in Management of Chronic Multiple Oral Ulcers","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-03-13","conditions":"Oral Ulcer Due to Pemphius Vularis, Oral Ulcer Due to Benign Mucous Membrane Pemphioid, Oral Ulcer Due to Steven Johnson's Syndrome","enrollment":804},{"nctId":"NCT03592342","phase":"PHASE2","title":"Intra-oral Treatment of OLP With Rivelin®-CLO Patches","status":"COMPLETED","sponsor":"Dermtreat","startDate":"2018-06-28","conditions":"Oral Lichen Planus","enrollment":140},{"nctId":"NCT03961126","phase":"PHASE2","title":"Evaluation of Vulvar Lichen Sclerosus Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma.","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2017-09-06","conditions":"Vulvar Lichen Sclerosus","enrollment":20},{"nctId":"NCT03386643","phase":"PHASE2","title":"Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2017-11-06","conditions":"Oral Lichen Planus","enrollment":22},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT03286582","phase":"PHASE2","title":"A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid","status":"TERMINATED","sponsor":"TWi Biotechnology, Inc.","startDate":"2017-09-05","conditions":"Bullous Pemphigoid","enrollment":10},{"nctId":"NCT02319616","phase":"PHASE1, PHASE2","title":"Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2016-11","conditions":"Toxic Epidermal Necrolysis","enrollment":""},{"nctId":"NCT00864500","phase":"PHASE1","title":"Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-11","conditions":"Healthy","enrollment":224},{"nctId":"NCT00864240","phase":"PHASE1","title":"The Dose-response \"Pilot\" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT03320460","phase":"NA","title":"Photobiomodulation in Oral Lichen Planus","status":"UNKNOWN","sponsor":"University of Nove de Julho","startDate":"2018-11-01","conditions":"Lichen Planus, Oral, Low-Level Light Therapy","enrollment":44},{"nctId":"NCT01235442","phase":"PHASE3","title":"Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Psoriasis","enrollment":592},{"nctId":"NCT02123966","phase":"PHASE2","title":"An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-07","conditions":"Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease","enrollment":10},{"nctId":"NCT02680717","phase":"PHASE1","title":"Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-03","conditions":"Scleroderma","enrollment":""},{"nctId":"NCT01323673","phase":"PHASE4","title":"Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-11-15","conditions":"Dermatitis, Chronic","enrollment":125},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT02131324","phase":"PHASE2","title":"DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2014-05-08","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02445807","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2015-12","conditions":"Chronic Stable Plaque Psoriasis","enrollment":265},{"nctId":"NCT02635204","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2015-12","conditions":"Psoriasis","enrollment":267},{"nctId":"NCT03026478","phase":"PHASE2","title":"Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus","status":"UNKNOWN","sponsor":"Garlapati Komali","startDate":"2016-05-06","conditions":"Oral Lichen Planus","enrollment":30},{"nctId":"NCT03453190","phase":"PHASE4","title":"Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis","status":"UNKNOWN","sponsor":"Washington Dermatology Center","startDate":"2018-02-25","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT03399526","phase":"PHASE1","title":"1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02936492","phase":"PHASE1","title":"BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-10-24","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT02416531","phase":"NA","title":"Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser","status":"COMPLETED","sponsor":"Daniela de Fátima Teixeira da Silva","startDate":"2015-01","conditions":"Vulvar Lichen Sclerosus","enrollment":30},{"nctId":"NCT00842153","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-11","conditions":"Psoriasis","enrollment":58},{"nctId":"NCT01381445","phase":"PHASE1","title":"A Study Assessing GW870086's Potential to Cause Skin Thinning","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-14","conditions":"Dermatitis, Atopic","enrollment":20},{"nctId":"NCT03089775","phase":"PHASE1","title":"Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis","status":"COMPLETED","sponsor":"Fresh Tracks Therapeutics, Inc.","startDate":"2017-03-14","conditions":"Contact Dermatitis","enrollment":47},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02940002","phase":"PHASE1","title":"BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-12","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT01313221","phase":"PHASE3","title":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-04","conditions":"Psoriasis","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Topical"},"crossReferences":{"chemblId":"CHEMBL1201362"},"_approvalHistory":[{"date":"20220217","type":"ORIG","sponsor":"QUAGEN","applicationNumber":"ANDA211240"},{"date":"20171027","type":"ORIG","sponsor":"ZYDUS PHARMS","applicationNumber":"ANDA210199"},{"date":"20221007","type":"SUPPL","sponsor":"ZYDUS PHARMS","applicationNumber":"ANDA210199"},{"date":"20171128","type":"ORIG","sponsor":"PRIMUS PHARMS","applicationNumber":"NDA209483"},{"date":"20191002","type":"ORIG","sponsor":"ALEMBIC","applicationNumber":"ANDA211191"},{"date":"20151123","type":"ORIG","sponsor":"NOVEL LABS INC","applicationNumber":"ANDA206075"}],"publicationCount":1523,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CLOBETASOL","genericName":"CLOBETASOL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:40:22.787415+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}